Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

2.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increasing Transfection of Human Monocyte-Derived Dendritic Cells by Optimizing Lipid Nanoparticle Ionizable Lipid and mRNA Uridine Modification.

Pharmaceutics·2026
Same author

DRP1 depletion protects NK cells from hypoxia-induced dysfunction.

Redox report : communications in free radical research·2026
Same author

A Minimally Invasive Transthoracic Injection Technique for Reproducible Intrapleural Delivery in Mice.

Methods and protocols·2025
Same author

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.

Antioxidants (Basel, Switzerland)·2023
Same author

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer.

Oncoimmunology·2023
Same author

Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model.

Pharmaceutics·2022

Related Experiment Video

Updated: Feb 25, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.7K

Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use.

J M J Van den Bergh1, E L J M Smits1,2, M Versteven1

  • 1Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium.

Journal of Immunology Research
|August 9, 2017
PubMed
Summary

Engineered dendritic cell (DC) vaccines can now transpresent interleukin-15 (IL-15) to enhance T-cell responses. This improved DC vaccine strategy boosts antitumor immunity and shows promise for cancer therapy.

More Related Videos

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

11.2K
Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface
13:36

Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface

Published on: October 20, 2023

4.3K

Related Experiment Videos

Last Updated: Feb 25, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.7K
Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

11.2K
Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface
13:36

Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface

Published on: October 20, 2023

4.3K

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • Dendritic cell (DC)-based vaccines are safe and effective second-line cancer therapies.
  • Improving overall survival requires more immunostimulatory DC vaccines.
  • Interleukin-15 (IL-15) is crucial for boosting antitumor immune responses.

Purpose of the Study:

  • To redesign DC vaccine generation for IL-15 transpresentation to IL-15Rβγ-expressing cells.
  • To enhance the antitumor immune response through modified DC vaccines.

Main Methods:

  • Electroporation of mature DCs with messenger RNA encoding IL-15 and IL-15 receptor alpha (IL-15Rα).
  • Assessment of DC surface marker expression, cytokine production, and migratory capacity.
  • Evaluation of IL-15-transpresenting DCs' ability to induce T-cell proliferation and activation.

Main Results:

  • Engineered DCs showed high surface IL-15 expression without altering DC markers or function.
  • IL-15-transpresenting DCs effectively induced T-cell proliferation.
  • These DCs demonstrated superior tumor antigen-specific T-cell activation compared to controls.

Conclusions:

  • Clinical-grade DCs can be safely engineered to transpresent IL-15 in a cost-effective manner.
  • This approach enhances the transfer of immune-stimulating IL-15 signals to effector cells.
  • Modified DC vaccines hold potential for improving cancer immunotherapy outcomes.